Form 4: NeoGenomics Director Michael Kelly Boosts Stake with $38,000 Stock Purchase

NeoGenomics Inc. Director Michael Aaron Kelly has increased his beneficial ownership in the company by purchasing 5,000 shares of common stock for $7.60 per share.

Summary

• Director Michael Aaron Kelly acquired 5,000 shares of NeoGenomics Inc. common stock on May 27, 2025.
• The purchase price was $7.60 per share, totaling $38,000.
• Following this transaction, Mr. Kelly directly owns 31,755 shares of common stock.
• An additional 5,000 shares are indirectly owned through the Michael and Bonnie Kelly Revocable Trust.
• Mr. Kelly also holds various stock options and restricted stock units, including 2,223 options at $37.53, 3,714 options at $40.9, 13,882 options at $8.1, 8,353 options at $14.82, 8,672 options at $13.71, and 12,254 restricted stock units.

Sentiment

Score: 7

Explanation: The sentiment is positive due to insider buying by a director, which typically signals confidence. However, the relatively small size of the purchase and the fact that the purchase price is significantly below some of the director's option strike prices temper the overall positive sentiment, suggesting the stock may have seen a substantial decline.

Positives

• Insider buying by a Director signals confidence in the company's future prospects.
• The purchase increases the Director's direct and indirect beneficial ownership in the company.

Negatives

• The purchase price of $7.60 per share is significantly lower than some of the strike prices of existing stock options held by the director (e.g., $37.53, $40.9, $14.82), which could imply a substantial decline in the stock price from previous highs.

Future Outlook

NA

Industry Context

This transaction reflects an insider's investment decision within the biotechnology and healthcare diagnostics sector, indicating a belief in the company's value proposition or future growth, despite potential market volatility or specific company challenges.

Comparison to Industry Standards

• Insider buying, particularly by a director, is generally viewed positively across all industries as it aligns management's interests with shareholders.
• The specific amount of $38,000 is a modest investment for a director, but the act of buying, especially when the stock price is lower than previous option strike prices, can be a signal.
• Comparable companies in the diagnostics space, such as Guardant Health (GH) or Exact Sciences (EXAS), often see similar insider transactions, which are closely watched by investors for sentiment indicators.

Related Party Transactions

• 5,000 shares of common stock are indirectly owned through the Michael and Bonnie Kelly Revocable Trust DTD 05/02/2016, where Michael Kelly is a trustee.

Stakeholder Impact

• Shareholders: The insider purchase may instill confidence among existing shareholders and attract potential investors, potentially leading to positive share price movement.
• Management: The transaction aligns the director's financial interests more closely with the company's performance.

Key Dates

Recommendation

Keywords

NeoGenomics, NEO, SEC Form 4, Insider Trading, Stock Purchase, Director Stock Acquisition, Michael Aaron Kelly, Beneficial Ownership, Equity Transaction, Biotechnology, Healthcare Diagnostics